CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

Background Probody® therapeutics are antibody prodrugs designed to be activated by tumor-associated proteases. This conditional activation restricts antibody binding to the tumor microenvironment, thereby minimizing ‘off-tumor’ toxicity. Here, we report the phase 1 data from the first-in-human study...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Omid Hamid, Fiona Thistlethwaite, Johanna Bendell, Ruth Plummer, Patrick A Ott, Rachel E Sanborn, Karen A Autio, Valentina Boni, Elisabeth GE de Vries, Javier Garcia-Corbacho, Daniel C Cho, Mark Stroh, Lawrence Lu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMJ Publishing Group 2021-07-01
coleção:	Journal for ImmunoTherapy of Cancer
Acesso em linha:	https://jitc.bmj.com/content/9/7/e002446.full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!